Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Posts 16-Percent Rise in Q1 Revenue Atop R&D and Profit Growth

NEW YORK (GenomeWeb News) — Bruker BioSciences today said first-quarter revenues increased 16 percent as R&D spending rose 11 percent and profit grew 19 percent.
 
Total receipts for the three months ended March 31 increased to $110.5 million from $94.9 million year over year.
 
Product revenue increased 14 percent to $95.4 million; service revenue increased 43 percent to $15 million; and “other” revenue contracted 76 percent to $154,000.
 
R&D spending rose to $13.6 million from $12.3 million in the year-ago period.
 
CEO Frank Laukien said the company saw “strong year-over-year growth and solid improvements in our gross margins and operating income.”
 
Bruker said profit rose to $3.9 million from $3.3 million in the year-ago period.
 
Bruker said it had around $55.7 million in cash, equivalents, and short-term investments as of March 31.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.